Wedbush Weighs in on Apellis Pharmaceuticals, Inc.’s FY2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) – Research analysts at Wedbush decreased their FY2025 EPS estimates for shares of Apellis Pharmaceuticals in a research note issued on Monday, January 23rd. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $2.24 for the year, down from their prior estimate of $2.37. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($6.27) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2026 earnings at $6.01 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) last issued its quarterly earnings results on Monday, November 7th. The company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.27). The business had revenue of $22.06 million during the quarter, compared to analyst estimates of $19.82 million. Apellis Pharmaceuticals had a negative net margin of 560.92% and a negative return on equity of 194.70%.

Several other research analysts also recently issued reports on APLS. JPMorgan Chase & Co. dropped their price objective on shares of Apellis Pharmaceuticals from $81.00 to $79.00 and set an “overweight” rating on the stock in a report on Tuesday, November 15th. Jefferies Financial Group cut shares of Apellis Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $70.00 to $40.00 in a research report on Thursday, November 10th. Credit Suisse Group lowered their target price on Apellis Pharmaceuticals from $45.00 to $43.00 and set a “neutral” rating for the company in a report on Tuesday, November 8th. Wells Fargo & Company downgraded Apellis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $83.00 to $58.00 in a research report on Monday, January 2nd. Finally, Raymond James increased their price target on Apellis Pharmaceuticals from $113.00 to $123.00 and gave the company a “strong-buy” rating in a research note on Tuesday, October 18th. One analyst has rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $71.23.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $51.70 on Tuesday. The firm has a market cap of $5.72 billion, a P/E ratio of -8.29 and a beta of 1.13. The stock’s 50-day moving average is $50.28 and its two-hundred day moving average is $55.72. The company has a debt-to-equity ratio of 0.30, a current ratio of 7.21 and a quick ratio of 6.69. Apellis Pharmaceuticals has a fifty-two week low of $33.32 and a fifty-two week high of $70.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in APLS. DekaBank Deutsche Girozentrale lifted its stake in shares of Apellis Pharmaceuticals by 116.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 57,700 shares of the company’s stock valued at $2,549,000 after purchasing an additional 31,000 shares during the last quarter. Harbour Capital Advisors LLC bought a new position in Apellis Pharmaceuticals in the 3rd quarter valued at $392,000. HC Advisors LLC increased its stake in Apellis Pharmaceuticals by 4.4% in the second quarter. HC Advisors LLC now owns 7,179 shares of the company’s stock worth $325,000 after purchasing an additional 300 shares during the period. Mackenzie Financial Corp lifted its holdings in Apellis Pharmaceuticals by 211.9% during the 3rd quarter. Mackenzie Financial Corp now owns 46,151 shares of the company’s stock valued at $3,152,000 after buying an additional 31,355 shares in the last quarter. Finally, Strs Ohio raised its stake in shares of Apellis Pharmaceuticals by 40.2% during the third quarter. Strs Ohio now owns 12,900 shares of the company’s stock valued at $881,000 after acquiring an additional 3,700 shares in the last quarter. 87.26% of the stock is currently owned by institutional investors.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 500 shares of Apellis Pharmaceuticals stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $50.70, for a total value of $25,350.00. Following the transaction, the director now directly owns 132,797 shares of the company’s stock, valued at $6,732,807.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director A. Sinclair Dunlop sold 500 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $50.70, for a total transaction of $25,350.00. Following the completion of the transaction, the director now directly owns 132,797 shares in the company, valued at $6,732,807.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Cedric Francois sold 28,200 shares of the company’s stock in a transaction that occurred on Monday, December 19th. The shares were sold at an average price of $52.06, for a total value of $1,468,092.00. Following the completion of the transaction, the chief executive officer now directly owns 965,128 shares in the company, valued at $50,244,563.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 87,700 shares of company stock worth $4,374,870. 8.00% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Company Profile

(Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.